TrialJournal of clinical psychopharmacology2017

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.

Maria Gasior et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.